BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

BioNexus Gene Lab Corp. (NASDAQ:BGLC) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 14,642 shares, a decrease of 85.2% from the June 15th total of 99,209 shares. Based on an average trading volume of 21,386 shares, the short-interest ratio is presently 0.7 days. Currently, 0.6% of the company’s stock are sold short.

Institutional Trading of BioNexus Gene Lab

A hedge fund recently raised its stake in BioNexus Gene Lab stock. DRW Securities LLC grew its position in BioNexus Gene Lab Corp. (NASDAQ:BGLC) by 226.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,830 shares of the company’s stock after acquiring an additional 33,179 shares during the period. DRW Securities LLC owned about 2.02% of BioNexus Gene Lab worth $189,000 at the end of the most recent quarter. Institutional investors own 18.85% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of BioNexus Gene Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, BioNexus Gene Lab has an average rating of “Sell”.

BioNexus Gene Lab Stock Up 4.6%

NASDAQ BGLC traded up $0.08 during trading on Friday, hitting $1.81. The company’s stock had a trading volume of 9,400 shares, compared to its average volume of 26,459. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.53 and a quick ratio of 5.69. The company has a market cap of $4.38 million, a PE ratio of -1.22 and a beta of 4.08. The business’s 50 day simple moving average is $2.14 and its 200-day simple moving average is $2.53. BioNexus Gene Lab has a fifty-two week low of $1.07 and a fifty-two week high of $8.98.

BioNexus Gene Lab (NASDAQ:BGLC) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. BioNexus Gene Lab had a negative net margin of 54.70% and a negative return on equity of 37.43%. The company had revenue of $0.02 million for the quarter.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.